Suvretta Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Suvretta Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,333	Closed	-$6K	–	108
2022 Q1	$6K	Hold	33,333	–	–	﹤0.01%	87
2021 Q4	$19K	Hold	33,333	–	–	﹤0.01%	94
2021 Q3	$24K	Hold	33,333	–	–	﹤0.01%	105
2021 Q2	$35K	Hold	33,333	–	–	﹤0.01%	121
2021 Q1	$42K	Buy	+33,333	New	+$54K	﹤0.01%	105

Other funds holding EUCRW

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Suvretta Capital Management's EUCRW Position: Q2 2022 in Review

Suvretta Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2022, closing a stake of 33,333 shares — an estimated $6K sold.

Suvretta Capital Management first reported a position in EUCRW in Q1 2021 and held it in 5 quarters. The position peaked at $42K in Q1 2021. 26 funds tracked by Wall St. Rank hold EUCRW as of Q2 2022.

Suvretta Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2022 after selling out during the quarter.
Suvretta Capital Management sold 33,333 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2022, an estimated $6K.
Suvretta Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 5 quarters.
Suvretta Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $42K in Q1 2021.
26 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2022.

Based on Suvretta Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.